Assessing Optimal XRB Initiation Points in Jail
Key facts
- Who runs it
- NYU Langone Health
- Where
- Boston, New Brunswick, New York, and Springfield, United StatesSee the 4 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 50 people, planned
- Started
- 2 Jun 2025
- Expected to end
- 1 Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Extended-Release Buprenorphine (XRB)
- Sublingual Buprenorphine (SLB)
- Record updated
- 7 August 2026
Who can take part
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Incarcerated men able to provide written informed consent in English.*
- Unsentenced
- Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days
- Minimum anticipated jail stay is 4 days
- Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated)
Who cannot take part
- Chronic pain requiring opioid pain management or other contraindicated medications
- Allergy, hypersensitivity or medical contraindication to either medication
- Sentenced
Where in United States
- Tufts University Health SciencesBoston, United StatesContact: Thomas Stopka, Ph.D. (principal investigator)Taking people
- Middlesex County House of CorrectionsNew Brunswick, United StatesContact: Kashif Siddiqi (principal investigator)Taking people
- NYU Langone Health - 180 Madison AveNew York, United StatesContact: David FarabeeTaking people
- Baystate HealthSpringfield, United StatesContact: Peter Friedmann, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Corrections (MCHOC) as pre-trial detainees will be randomized at admission on a 1:1 basis to be inducted onto extended-release buprenorphine (XRB) at the time of admission (experimental condition) or remain in SLB (E-TAU; all participants will also receive naloxone). The two approaches will be compared with regard to (1) the percentage of participants released from jail with at least 7 days of buprenorphine in their system, (2) percentage of participants continuing MOUD treatment in the community, and (3) infractions related to buprenorphine diversion.
The 2 groups in the trial
- Transition to Extended-Release Buprenorphine (XRB)Treatment being tested
Participants randomized to transition to treatment with XRB.
Treatment: Extended-Release Buprenorphine (XRB)
- Sublingual Buprenorphine (SLB) MaintenanceExisting treatment, for comparison
Participants randomized to remain on-treatment with SLB.
Treatment: Sublingual Buprenorphine (SLB)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Assessing Optimal Extended-Release Buprenorphine (XRB) Initiation Points in Jail
- Record updated
- 7 August 2026